お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙:免疫蛍光アッセイの世界市場 (~2026年):製品 (試薬・機器・抗体・キット・消耗品および付属品)・タイプ (直接・間接)・疾患 (感染症・その他)・エンドユーザー (CRO)・地域別
市場調査レポート
商品コード
987770

免疫蛍光アッセイの世界市場 (~2026年):製品 (試薬・機器・抗体・キット・消耗品および付属品)・タイプ (直接・間接)・疾患 (感染症・その他)・エンドユーザー (CRO)・地域別

Immunofluorescence Assay Market by Product (Reagent, Instruments, Antibodies, Kits, Consumables & Accessories), Type (Direct, Indirect), Disease (Infectious Disease, Other Diseases), End User (Contract Research Organizations) - Global Forecast to 2026

出版日: | 発行: MarketsandMarkets | ページ情報: 英文 204 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.15円
免疫蛍光アッセイの世界市場 (~2026年):製品 (試薬・機器・抗体・キット・消耗品および付属品)・タイプ (直接・間接)・疾患 (感染症・その他)・エンドユーザー (CRO)・地域別
出版日: 2021年02月03日
発行: MarketsandMarkets
ページ情報: 英文 204 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

世界の免疫蛍光アッセイの市場規模は予測期間中6.0%のCAGRで推移し、2021年の26億米ドルから、2026年には35億米ドルの規模に成長すると予測されています。慢性疾患の有病率の増加、R&D費および医療費の増加などの要因が同市場の成長を推進しています。また、新興市場が今後数年にわたって参入事業者に成長機会を示す見通しです。一方で、抗体の品質への懸念が同市場のさらなる成長の課題となる見通しです。

製品別で見ると、キットの部門が予測期間中最大の成長率を示すと予測されています。CRO、学術機関、研究機関は単一のプロバイダーによる完全なソリューションを求めており、同部門の成長を推進しています。また、タイプ別では、感度、柔軟性、信号のより良い増幅性、低コストなどの利点から、間接免疫蛍光の部門が予測期間中最大のCAGRを示す見通しです。

当レポートでは、世界の免疫蛍光アッセイの市場を調査し、市場の定義と概要、バリューチェーン、新型コロナウイルス感染症 (COVID-19) およびその他の市場影響因子の分析、市場規模の推移・予測、製品・タイプ・疾患・エンドユーザー・地域/主要国など各種区分別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要

  • 市場力学
    • 促進要因
    • 抑制要因
    • 市場機会
    • 課題
  • COVID-19の影響
  • 価格分析
  • バリューチェーン
  • サプライチェーン分析
  • エコシステム分析
  • PESTLE分析

第6章 市場分析・予測:製品別

  • 試薬
    • ステイン・染料
    • 培地・血清
    • 固定液
    • バッファ
    • プローブ
    • 溶剤
    • その他
  • 機器
    • 顕微鏡
    • 画像解析システム
  • 抗体
    • 一次抗体
    • 二次抗体
  • キット
  • 消耗品・付属品

第7章 市場分析・予測:タイプ別

  • 間接免疫蛍光法
  • 直接免疫蛍光法

第8章 市場分析・予測:疾患別

  • 感染症
  • 心血管疾患
  • 自己免疫疾患
  • その他

第9章 市場分析・予測:エンドユーザー別

  • 製薬・バイオテクノロジー企業
  • 学術機関・研究機関
  • 病院・診断センター
  • CRO

第10章 市場分析・予測:地域・主要国別

  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • その他
  • ラテンアメリカ
  • 中東・アフリカ

第11章 競合情勢

  • 概要
  • 市場シェア分析
  • 競合シナリオ
  • 企業評価マトリックス
  • 新興企業・中小企業の競合リーダーシップマッピング

第12章 企業プロファイル

  • THERMO FISHER SCIENTIFIC, INC.
  • ABCAM PLC
  • BIO-RAD LABORATORIES, INC.
  • PERKINELMER, INC.
  • MERCK KGAA
  • WERFEN COMPANY
  • CELL SIGNALING TECHNOLOGY, INC.
  • MEDIPAN GMBH
  • SINO BIOLOGICAL, INC.
  • DANAHER CORPORATION
  • MARAVAI LIFESCIENCES
  • ENZO BIOCHEM, INC.
  • BECTON, DICKINSON AND COMPANY (BD)
  • OLYMPUS CORPORATION
  • NIKON CORPORATION
  • BRUKER CORPORATION
  • AGILENT TECHNOLOGIES
  • ZYAGEN, INC.
  • CELLABS
  • J. MITRA & CO. PVT. LTD.
  • ABNOVA CORPORATION
  • EPIGENTEK GROUP
  • ELABSCIENCE, INC.
  • AESKU.GROUP GMBH
  • MAXVISION BIOSCIENCES, INC.

第13章 付録

目次
Product Code: BT 6044

The global immunofluorescence assays market is projected to reach USD 3.5 billion by 2026 from USD 2.6 billion in 2021, at a CAGR of 6.0% during the forecast period. The growth in this market is primarily attributed to the increasing prevalence of chronic diseases and rising R&D spending & healthcare expenditure. Emerging markets are expected to provide growth opportunities for players operating in the immunofluorescence assays market in the coming years. However, quality concerns over antibodies are the major challenge in this market.

"The kits segment accounted for the highest growth rate in the Immunofluorescence assay market, by product, during the forecast period"

The Immunofluorescence assay market is segmented into reagents, instruments, antibodies, kits, and consumables and accessories. The kits segment accounted for the highest growth rate in the Immunofluorescence assay market in 2020. The demand for complete solutions from a single provider, like closed-system reagents with calibrated measurements of the required quantity of reagents and controls, among CROs, academic institutes, and research institutes is growing, contributing to this segment's high growth rate.

"Indirect immunofluorescence segment accounted for the highest CAGR"

Based on type, the immunofluorescence assays market is segmented into indirect immunofluorescence and direct immunofluorescence. In 2020, indirect immunofluorescence accounted for accounted for the highest growth rate. The major factors driving the growth of this segment are its advantages such as sensitivity, flexibility, better amplification of the signal, and lower cost over direct immunofluorescence.

"Cancer segment accounted for the highest CAGR"

Based on disease, the immunofluorescence assays market is segmented into cancer, infectious diseases, autoimmune diseases, cardiovascular diseases, and other diseases. In 2020, the cancer segment accounted for the highest growth rate. Increasing prevalence of cancer globally and the widespread adoption of immunofluorescence techniques for the study and diagnosis of cancer are the major factors driving this segment's growth.

"Hospitals & Diagnostic Centers segment accounted for the highest CAGR"

Based on end user, the immunofluorescence assays market is segmented intopharmaceutical & biotechnology companies, academic & research institutes, hospitals & diagnostics centers, and contract research organizations. In 2020, the hospitals & diagnostics centers segment accounted for the highest growth rate. This can be attributed to the rising number of cases for various diseases coupled with the increasing number of hospitals worldwide are the major driving factors for this segment's growth.

"Asia Pacific: The fastest-growing country in the Immunofluorescence assay market"

The Immunofluorescence assay market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Asia Pacific is projected to register the highest CAGR during the forecast period. Factors such as improving healthcare infrastructure, increasing healthcare spending, and favorable government initiatives are driving the growth of the immunofluorescence assay market in Asia Pacific.

The primary interviews conducted for this report can be categorized as follows:

  • By Company Type: Tier 1 - 32%, Tier 2 - 44%, and Tier 3 - 24%
  • By Designation: C-level - 30%, D-level - 34%, and Others - 36%
  • By Region: North America- 50%, Europe- 32%, APAC-10%, RoW- 8%

Lists of Companies Profiled in the Report:

  • Thermo Fisher Scientific, Inc. (US)
  • Abcam plc (UK)
  • Bio-Rad Laboratories, Inc. (US)
  • PerkinElmer Inc. (US)
  • Merck KGaA (Germany)
  • Werfen Company (Spain)
  • Cell Signaling Technology, Inc. (US)
  • MEDIPAN GmbH (Germany)
  • Sino Biological, Inc. (China)
  • Danaher Corporation (US)
  • Maravai LifeSciences (US)
  • Enzo Biochem, Inc. (US)
  • Becton, Dickinson and Company (US)
  • Olympus Corporation (Japan)
  • Nikon Corporation (Japan)
  • Bruker Corporation (US)
  • Agilent Technologies (US)
  • Zyagen, Inc. (US)
  • Cellabs (Australia)
  • J. Mitra & Co. Pvt. Ltd. (India)
  • Abnova Corporation (Taiwan)
  • EpiGentek Group (US)
  • Elabscience, Inc. (US)
  • AESKU GROUP GmbH (Germany)
  • MaxVision Biosciences Inc. (Canada)

Research Coverage:

This report provides a detailed picture of the Immunofluorescence assay market. It aims at estimating the size and future growth potential of the market across different segments, such as the product, type, disease, end user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall Immunofluorescence assay market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS & EXCLUSIONS
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • FIGURE 1 IMMUNOFLUORESCENCE ASSAYS MARKET
    • 1.3.2 YEARS CONSIDERED FOR THE STUDY
    • 1.3.3 CURRENCY
  • 1.4 STAKEHOLDERS
  • 1.5 LIMITATIONS
  • 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 2 IMMUNOFLUORESCENCE ASSAYS MARKET: RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
    • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
      • 2.1.2.1 Key data from primary sources
  • 2.2 MARKET SIZE ESTIMATION
    • 2.2.1 BOTTOM-UP APPROACH
    • FIGURE 4 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
    • 2.2.2 TOP-DOWN APPROACH
    • FIGURE 5 TOP-DOWN APPROACH
    • 2.2.3 GROWTH FORECAST
  • 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 6 DATA TRIANGULATION METHODOLOGY
  • 2.4 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY

    • FIGURE 7 IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2021 VS. 2026 (USD MILLION)
    • FIGURE 8 IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2018 VS. 2023 (USD MILLION)
    • FIGURE 9 IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION)
    • FIGURE 10 IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
    • FIGURE 11 GEOGRAPHIC SNAPSHOT: IMMUNOFLUORESCENCE ASSAYS MARKET

4 PREMIUM INSIGHTS

  • 4.1 IMMUNOFLUORESCENCE ASSAYS MARKET OVERVIEW
    • FIGURE 12 RISING PREVALENCE OF CHRONIC DISEASES TO DRIVE MARKET GROWTH
  • 4.2 ASIA PACIFIC: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE & COUNTRY (2020)
    • FIGURE 13 INDIRECT IMMUNOFLUORESCENCE SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE ASIA PACIFIC MARKET IN 2020
  • 4.3 IMMUNOFLUORESCENCE ASSAYS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 14 CHINA TO REGISTER THE HIGHEST GROWTH IN THE FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 KEY MARKET DYNAMICS
    • FIGURE 15 IMMUNOFLUORESCENCE ASSAYS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Increasing prevalence of chronic diseases
    • TABLE 1 INCIDENCE OF CANCER, 2018 VS. 2040
      • 5.2.1.2 Rising R&D and healthcare spending
    • FIGURE 16 PHARMACEUTICAL R&D EXPENDITURE, BY GEOGRAPHY, 2010-2016
    • FIGURE 17 GLOBAL CURRENT HEALTH EXPENDITURE PER CAPITA, 2015-2018
      • 5.2.1.3 Growing industry-academia collaboration
      • 5.2.1.4 Increasing government funding for life science research
    • TABLE 2 GOVERNMENT FUNDING FOR LIFE SCIENCE RESEARCH (2017-2020)
      • 5.2.1.5 Growing awareness about early disease detection
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High instrument costs
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 High growth opportunities in emerging markets
    • TABLE 3 DIABETES PREVALENCE IN EMERGING ECONOMIES, 2019 VS. 2030 VS. 2045
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Quality concerns over research antibodies
      • 5.2.4.2 Lack of skilled professionals
    • TABLE 4 NUMBER OF PATHOLOGISTS PER 100,000 POPULATION, BY COUNTRY, 2018
  • 5.3 COVID-19 IMPACT ON THE IMMUNOFLUORESCENCE ASSAYS MARKET
    • TABLE 5 IMMUNOFLUORESCENCE ASSAY TESTS APPROVED FOR COVID-19 DIAGNOSTICS
  • 5.4 PRICING ANALYSIS
    • TABLE 6 IMMUNOFLUORESCENCE ASSAY PRODUCTS, AVERAGE SELLING PRICES (IN USD)
  • 5.5 VALUE CHAIN ANALYSIS
    • FIGURE 18 MAJOR VALUE IS ADDED DURING THE MANUFACTURING AND ASSEMBLY PHASE
  • 5.6 SUPPLY CHAIN ANALYSIS
    • FIGURE 19 DIRECT DISTRIBUTION-STRATEGY PREFERRED BY PROMINENT COMPANIES
  • 5.7 ECOSYSTEM ANALYSIS OF THE IMMUNOFLUORESCENCE ASSAYS MARKET
    • FIGURE 20 ECOSYSTEM ANALYSIS OF THE IMMUNOFLUORESCENCE ASSAYS MARKET
  • 5.8 PESTLE ANALYSIS

6 IMMUNOFLUORESCENCE ASSAY MARKET, BY PRODUCT

  • 6.1 INTRODUCTION
    • TABLE 7 IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
  • 6.2 REAGENTS
    • TABLE 8 IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 9 IMMUNOFLUORESCENCE REAGENTS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • 6.2.1 STAINS & DYES
      • 6.2.1.1 Stains and dyes accounted for the largest share of the reagents segment in 2020
    • TABLE 10 IMMUNOFLUORESCENCE STAINS & DYES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • 6.2.2 MEDIA & SERA
      • 6.2.2.1 Serum-free media eliminates the risk of contamination by viruses
    • TABLE 11 IMMUNOFLUORESCENCE MEDIA & SERA MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • 6.2.3 FIXATIVES
      • 6.2.3.1 Fixative agents are required for the preservation of morphology and the antigenicity of target molecules
    • TABLE 12 IMMUNOFLUORESCENCE FIXATIVES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • 6.2.4 BUFFERS
      • 6.2.4.1 Buffers are widely used in drug development applications
    • TABLE 13 IMMUNOFLUORESCENCE BUFFERS MARKET, BY COUNTRY, 2019-2026(USD MILLION)
    • 6.2.5 PROBES
      • 6.2.5.1 The use of probes in research is rising owing to its versatile and quantitative capabilities
    • TABLE 14 IMMUNOFLUORESCENCE PROBES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • 6.2.6 SOLVENTS
      • 6.2.6.1 Organic solvents are widely used in pharmaceutical processes and immunofluorescence assays
    • TABLE 15 IMMUNOFLUORESCENCE SOLVENTS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • 6.2.7 OTHER REAGENTS
    • TABLE 16 OTHER IMMUNOFLUORESCENCE REAGENTS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
  • 6.3 INSTRUMENTS
    • TABLE 17 IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 18 IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • 6.3.1 MICROSCOPES
      • 6.3.1.1 Technological advancements in microscopy techniques propel segment growth
    • TABLE 19 IMMUNOFLUORESCENCE MICROSCOPES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • 6.3.2 IMAGING ANALYSIS SYSTEMS
      • 6.3.2.1 Imaging analysis systems are widely used in diagnostics and clinical research
    • TABLE 20 IMMUNOFLUORESCENCE IMAGING ANALYSIS SYSTEMS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
  • 6.4 ANTIBODIES
    • TABLE 21 IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019-2026(USD MILLION)
    • TABLE 22 IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • 6.4.1 PRIMARY ANTIBODIES
      • 6.4.1.1 The increasing demand for accurate and reliable antibodies coupled with rising R&D expenditure drives segment growth
    • TABLE 23 PRIMARY IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • 6.4.2 SECONDARY ANTIBODIES
      • 6.4.2.1 The low cost of production and versatility have ensured stable growth in the market for secondary antibodies
    • TABLE 24 SECONDARY IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
  • 6.5 KITS
    • 6.5.1 THE DEMAND FOR COMPLETE SOLUTIONS AMONG END USERS DRIVES THE GROWTH OF THIS SEGMENT
    • TABLE 25 IMMUNOFLUORESCENCE KITS MARKET, BY COUNTRY, 2019-2026(USD MILLION)
  • 6.6 CONSUMABLES & ACCESSORIES
    • TABLE 26 IMMUNOFLUORESCENCE CONSUMABLES & ACCESSORIES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)

7 IMMUNOFLUORESCENCE ASSAY MARKET, BY TYPE

  • 7.1 INTRODUCTION
    • TABLE 27 GLOBAL IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 28 COMPARISON BETWEEN DIRECT AND INDIRECT IMMUNOFLUORESCENCE TECHNIQUES
  • 7.2 INDIRECT IMMUNOFLUORESCENCE
    • 7.2.1 INDIRECT IMMUNOFLUORESCENCE ACCOUNTED FOR THE LARGEST SHARE OF THE MARKET IN 2020
    • TABLE 29 GLOBAL INDIRECT IMMUNOFLUORESCENCE ASSAYS MARKET, BY REGION/COUNTRY, 2019-2026 (USD MILLION)
  • 7.3 DIRECT IMMUNOFLUORESCENCE
    • 7.3.1 THE HIGH COST ASSOCIATED WITH DIRECT IMMUNOFLUORESCENCE MAY LIMIT THE GROWTH OF THIS MARKET
    • TABLE 30 GLOBAL DIRECT IMMUNOFLUORESCENCE ASSAYS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)

8 IMMUNOFLUORESCENCE ASSAY MARKET, BY DISEASE

  • 8.1 INTRODUCTION
    • TABLE 31 IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019-2026 (USD MILLION)
  • 8.2 CANCER
    • 8.2.1 CANCER ACCOUNTED FOR THE LARGEST SHARE OF THE DISEASE SEGMENT IN 2020
    • TABLE 32 CANCER PREVALENCE, BY TYPE (2018)
    • TABLE 33 GLOBAL CANCER INCIDENCE, 2018 VS. 2025
    • TABLE 34 IMMUNOFLUORESCENCE ASSAYS MARKET FOR CANCER, BY COUNTRY, 2019-2026 (USD MILLION)
  • 8.3 INFECTIOUS DISEASES
    • 8.3.1 THE RISING PREVALENCE OF INFECTIOUS DISEASES TO INCREASE THE ADOPTION OF IMMUNOFLUORESCENCE ASSAY TECHNIQUES
    • TABLE 35 IMMUNOFLUORESCENCE ASSAYS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019-2026 (USD MILLION)
  • 8.4 CARDIOVASCULAR DISEASES
    • 8.4.1 THE HIGH INCIDENCE OF CVD TO INCREASE THE ADOPTION OF IMMUNOFLUORESCENCE IMAGING TECHNIQUES
    • TABLE 36 IMMUNOFLUORESCENCE ASSAYS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2019-2026 (USD MILLION)
  • 8.5 AUTOIMMUNE DISEASES
    • 8.5.1 THE PREVALENCE OF AUTOIMMUNE DISEASES HAVE INCREASED WORLDWIDE, THUS SUPPORTING THE GROWTH OF THIS SEGMENT
    • TABLE 37 PREVALENCE OF AIDS
    • TABLE 38 IMMUNOFLUORESCENCE ASSAYS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2019-2026 (USD MILLION)
  • 8.6 OTHER DISEASES
    • TABLE 39 IMMUNOFLUORESCENCE ASSAYS MARKET FOR OTHER DISEASES, BY COUNTRY, 2019-2026 (USD MILLION)

9 IMMUNOFLUORESCENCE ASSAY MARKET, BY END USER

  • 9.1 INTRODUCTION
    • TABLE 40 IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019-2026(USD MILLION)
  • 9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 9.2.1 PHARMA & BIOTECH COMPANIES ACCOUNTED FOR THE LARGEST SHARE OF THE END-USER SEGMENT IN 2020
    • TABLE 41 IMMUNOFLUORESCENCE ASSAYS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY/REGION, 2019-2026 (USD MILLION)
  • 9.3 ACADEMIC & RESEARCH INSTITUTES
    • 9.3.1 GROWING GOVERNMENT INVESTMENTS FOR R&D TO PROPEL MARKET GROWTH
    • TABLE 42 IMMUNOFLUORESCENCE ASSAYS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY/REGION, 2019-2026 (USD MILLION)
  • 9.4 HOSPITALS & DIAGNOSTIC CENTERS
    • 9.4.1 THE RISING PREVALENCE OF CHRONIC DISEASES TO SUPPORT THE GROWTH OF THIS SEGMENT
    • TABLE 43 IMMUNOFLUORESCENCE ASSAYS MARKET FOR HOSPITALS & DIAGNOSTIC CENTERS, BY COUNTRY/REGION, 2019-2026 (USD MILLION)
  • 9.5 CONTRACT RESEARCH ORGANIZATIONS
    • 9.5.1 EMERGING MARKETS ARE EXPECTED TO PROVIDE ROBUST GROWTH OPPORTUNITIES FOR CROS
    • TABLE 44 IMMUNOFLUORESCENCE ASSAYS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY/REGION, 2019-2026(USD MILLION)

10 IMMUNOFLUORESCENCE ASSAY MARKET, BY REGION

  • 10.1 INTRODUCTION
    • TABLE 45 IMMUNOFLUORESCENCE ASSAYS MARKET, BY REGION, 2019-2026 (USD MILLION)
  • 10.2 NORTH AMERICA
    • FIGURE 21 NORTH AMERICA: IMMUNOFLUORESCENCE ASSAYS MARKET, SNAPSHOT
    • TABLE 46 NORTH AMERICA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 47 NORTH AMERICA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 48 NORTH AMERICA: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 49 NORTH AMERICA: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 50 NORTH AMERICA: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 51 NORTH AMERICA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 52 NORTH AMERICA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019-2026 (USD MILLION)
    • TABLE 53 NORTH AMERICA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 10.2.1 US
      • 10.2.1.1 The US dominates the North American market in terms of market share
    • TABLE 54 US NIH BUDGET FOR VARIOUS DISCIPLINES, FY 2019 VS. FY 2020 (USD BILLION)
    • TABLE 55 US: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 56 US: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 57 US: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 58 US: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 59 US: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 60 US: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019-2026 (USD MILLION)
    • TABLE 61 US: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 10.2.2 CANADA
      • 10.2.2.1 Support from government organizations is driving the growth of the immunofluorescence assays market in Canada
    • TABLE 62 CANADA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 63 CANADA: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 64 CANADA: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 65 CANADA: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 66 CANADA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 67 CANADA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019-2026 (USD MILLION)
    • TABLE 68 CANADA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019-2026 (USD MILLION)
  • 10.3 EUROPE
    • TABLE 69 EUROPE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 70 EUROPE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 71 EUROPE: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 72 EUROPE: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 73 EUROPE: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 74 EUROPE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 75 EUROPE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019-2026 (USD MILLION)
    • TABLE 76 EUROPE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 10.3.1 GERMANY
      • 10.3.1.1 Germany holds the largest share of the European market
    • TABLE 77 RESEARCH GRANTS PROVIDED IN GERMANY, 2015-2019
    • TABLE 78 GERMANY: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 79 GERMANY: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 80 GERMANY: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 81 GERMANY: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 82 GERMANY: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 83 GERMANY: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019-2026 (USD MILLION)
    • TABLE 84 GERMANY: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 10.3.2 UK
      • 10.3.2.1 Growing R&D investments drive the market in the UK
    • TABLE 85 UK: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 86 UK: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 87 UK: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 88 UK: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 89 UK: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 90 UK: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019-2026 (USD MILLION)
    • TABLE 91 UK: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 10.3.3 FRANCE
      • 10.3.3.1 Rising research activity supports market growth in France
    • TABLE 92 FRANCE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 93 FRANCE: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 94 FRANCE: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 95 FRANCE: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 96 FRANCE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 97 FRANCE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019-2026 (USD MILLION)
    • TABLE 98 FRANCE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 10.3.4 ITALY
      • 10.3.4.1 Rising life science R&D and favorable funding scenario are key drivers of the Italian market
    • TABLE 99 ITALY: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 100 ITALY: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 101 ITALY: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 102 ITALY: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 103 ITALY: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 104 ITALY: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019-2026 (USD MILLION)
    • TABLE 105 ITALY: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 10.3.5 SPAIN
      • 10.3.5.1 Rising prevalence of chronic disease to support the market growth
    • TABLE 106 SPAIN: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 107 SPAIN: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 108 SPAIN: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 109 SPAIN: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 110 SPAIN: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 111 SPAIN: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019-2026 (USD MILLION)
    • TABLE 112 SPAIN: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 10.3.6 REST OF EUROPE
    • TABLE 113 ROE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 114 ROE: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 115 ROE: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 116 ROE: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 117 ROE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 118 ROE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019-2026 (USD MILLION)
    • TABLE 119 ROE: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019-2026 (USD MILLION)
  • 10.4 ASIA PACIFIC
    • FIGURE 22 ASIA PACIFIC: IMMUNOFLUORESCENCE ASSAYS MARKET SNAPSHOT
    • TABLE 120 APAC: IMMUNOFLUORESCENCE ASSAYS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 121 APAC: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 122 APAC: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 123 APAC: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 124 APAC: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 125 APAC: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 126 APAC: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019-2026 (USD MILLION)
    • TABLE 127 APAC: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 10.4.1 JAPAN
      • 10.4.1.1 Japan is the largest market for immunofluorescence assays in the APAC
    • TABLE 128 JAPAN: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 129 JAPAN: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 130 JAPAN: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 131 JAPAN: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 132 JAPAN: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 133 JAPAN: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019-2026 (USD MILLION)
    • TABLE 134 JAPAN: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 10.4.2 CHINA
      • 10.4.2.1 China is the fastest-growing market for immunofluorescence assays
    • TABLE 135 CHINA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 136 CHINA: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 137 CHINA: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 138 CHINA: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 139 CHINA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 140 CHINA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019-2026 (USD MILLION)
    • TABLE 141 CHINA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 10.4.3 INDIA
      • 10.4.3.1 Increasing government spending on healthcare to support market growth
    • TABLE 142 INDIA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 143 INDIA: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 144 INDIA: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 145 INDIA: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 146 INDIA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 147 INDIA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019-2026 (USD MILLION)
    • TABLE 148 INDIA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 10.4.4 REST OF ASIA PACIFIC
    • TABLE 149 ROAPAC: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 150 ROAPAC: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 151 ROAPAC: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 152 ROAPAC: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 153 ROAPAC: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 154 ROAPAC: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019-2026 (USD MILLION)
    • TABLE 155 ROAPAC: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019-2026 (USD MILLION)
  • 10.5 LATIN AMERICA
    • 10.5.1 GROWING CONTRACT RESEARCH & MANUFACTURING ACTIVITIES TO SUPPORT MARKET GROWTH
    • TABLE 156 LATIN AMERICA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 157 LATIN AMERICA: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 158 LATIN AMERICA: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 159 LATIN AMERICA: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 160 LATIN AMERICA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 161 LATIN AMERICA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019-2026 (USD MILLION)
    • TABLE 162 LATIN AMERICA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019-2026 (USD MILLION)
  • 10.6 MIDDLE EAST & AFRICA
    • 10.6.1 INADEQUATE RESEARCH INFRASTRUCTURE TO HAMPER THE MARKET GROWTH IN THE REGION
    • TABLE 163 MEA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY PRODUCT, 2019-2026 (USD MILLION)
    • TABLE 164 MEA: IMMUNOFLUORESCENCE REAGENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 165 MEA: IMMUNOFLUORESCENCE INSTRUMENTS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 166 MEA: IMMUNOFLUORESCENCE ANTIBODIES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 167 MEA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 168 MEA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY DISEASE, 2019-2026 (USD MILLION)
    • TABLE 169 MEA: IMMUNOFLUORESCENCE ASSAYS MARKET, BY END USER, 2019-2026 (USD MILLION)

11 COMPETITIVE LANDSCAPE

  • 11.1 OVERVIEW
    • FIGURE 23 KEY DEVELOPMENTS IN THE IMMUNOFLUORESCENCE ASSAYS MARKET (2017 TO 2020)
  • 11.2 MARKET SHARE ANALYSIS
    • FIGURE 24 IMMUNOFLUORESCENCE REAGENTS, KITS, ANTIBODIES, AND CONSUMABLE & ACCESSORIES MARKET SHARE, BY KEY PLAYER (2019)
    • FIGURE 25 IMMUNOFLUORESCENCE INSTRUMENTS MARKET SHARE, BY KEY PLAYER (2019)
  • 11.3 COMPETITIVE SCENARIO
    • 11.3.1 MARKET EVALUATION FRAMEWORK, 2017-2020
    • 11.3.2 PRODUCT LAUNCHES & APPROVALS
    • TABLE 170 PRODUCT LAUNCHES & APPROVALS
    • 11.3.3 AGREEMENTS & COLLABORATIONS
    • TABLE 171 AGREEMENTS & COLLABORATIONS
    • 11.3.4 ACQUISITIONS
    • TABLE 172 ACQUISITIONS
    • 11.3.5 EXPANSIONS
    • TABLE 173 EXPANSIONS
    • 11.3.6 OTHER DEVELOPMENTS
    • TABLE 174 OTHER DEVELOPMENTS
  • 11.4 COMPANY EVALUATION MATRIX DEFINITION AND METHODOLOGY
    • 11.4.1 VENDOR EXCLUSION CRITERIA
    • 11.4.2 STARS
    • 11.4.3 EMERGING LEADERS
    • 11.4.4 PERVASIVE PLAYERS
    • 11.4.5 PARTICIPANTS
    • FIGURE 26 IMMUNOFLUORESCENCE ASSAYS MARKET: COMPETITIVE LEADERSHIP MAPPING
  • 11.5 COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES
    • 11.5.1 PROGRESSIVE COMPANIES
    • 11.5.2 STARTING BLOCKS
    • 11.5.3 RESPONSIVE COMPANIES
    • 11.5.4 DYNAMIC COMPANIES
    • FIGURE 27 IMMUNOFLUORESCENCE ASSAYS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES

12 COMPANY PROFILES

  • (Business overview, Products offered, Recent developments & MnM View)**
  • 12.1 THERMO FISHER SCIENTIFIC, INC.
    • FIGURE 28 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2019)
  • 12.2 ABCAM PLC
    • FIGURE 29 ABCAM PLC: COMPANY SNAPSHOT (2020)
  • 12.3 BIO-RAD LABORATORIES, INC.
    • FIGURE 30 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2019)
  • 12.4 PERKINELMER, INC.
    • FIGURE 31 PERKINELMER: COMPANY SNAPSHOT (2019)
  • 12.5 MERCK KGAA
    • FIGURE 32 MERCK KGAA: COMPANY SNAPSHOT (2019)
  • 12.6 WERFEN COMPANY
    • FIGURE 33 WERFEN COMPANY: COMPANY SNAPSHOT (2019)
  • 12.7 CELL SIGNALING TECHNOLOGY, INC.
  • 12.8 MEDIPAN GMBH
  • 12.9 SINO BIOLOGICAL, INC.
  • 12.10 DANAHER CORPORATION
    • FIGURE 34 DANAHER CORPORATION: COMPANY SNAPSHOT (2019)
  • 12.11 MARAVAI LIFESCIENCES
    • FIGURE 35 MARAVAI LIFESCIENCES: COMPANY SNAPSHOT (2019)
  • 12.12 ENZO BIOCHEM, INC.
    • FIGURE 36 ENZO BIOCHEM, INC.: COMPANY SNAPSHOT (2019)
  • 12.13 BECTON, DICKINSON AND COMPANY (BD)
    • FIGURE 37 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2020)
  • 12.14 OLYMPUS CORPORATION
    • FIGURE 38 OLYMPUS CORPORATION: COMPANY SNAPSHOT (2020)
  • 12.15 NIKON CORPORATION
    • FIGURE 39 NIKON CORPORATION: COMPANY SNAPSHOT (2020)
  • 12.16 BRUKER CORPORATION
  • 12.17 AGILENT TECHNOLOGIES
  • 12.18 ZYAGEN, INC.
  • 12.19 CELLABS
  • 12.20 J. MITRA & CO. PVT. LTD.
  • 12.21 ABNOVA CORPORATION
  • 12.22 EPIGENTEK GROUP
  • 12.23 ELABSCIENCE, INC.
  • 12.24 AESKU.GROUP GMBH
  • 12.25 MAXVISION BIOSCIENCES, INC.
  • *Details on Business overview, Products offered, Recent developments & MnM View might not be captured in case of unlisted companies.

13 APPENDIX

  • 13.1 INDUSTRY INSIGHTS
  • 13.2 DISCUSSION GUIDE
  • 13.3 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.4 AVAILABLE CUSTOMIZATIONS
  • 13.5 RELATED REPORTS
  • 13.6 AUTHOR DETAILS
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.